Unauthorized change of immunosuppressants by patients with rheumatic diseases in the COVID-19 pandemic: a cross-sectional analysis of a patient survey

被引:0
作者
Simon Dahm
Joerg C. Henes
Sebastian J. Saur
机构
[1] University of Tuebingen,School of Medicine
[2] University Hospital Tuebingen,Centre for Interdisciplinary Clinical Immunology, Rheumatology and Auto
来源
Rheumatology International | 2023年 / 43卷
关键词
Surveys and questionnaires; Cross-sectional studies; COVID-19; SARS-CoV-2; Pandemic; Rheumatic disease; Fear; Compliance;
D O I
暂无
中图分类号
学科分类号
摘要
This study provides insight in behavior and perspective of rheumatic patients during the first COVID-19 wave. Especially, we analyzed the patients’ fear of COVID-19 and unauthorized change of immunosuppressive medication in consequence of their fear. We hereby provide data from 877 patients with valuable insights into the patients’ point of view. We retrospectively interviewed patients of our rheumatic university outpatient clinic. This way, we collected information about the patients’ personal point of view. Data like the rheumatic diagnosis and immunosuppressive medication was extracted from the health records. Statistical analysis was conducted using IBM® SPSS® Statistics (version 26). A total of 877 patients were included into our study. We could show that fear of COVID-19 was clearly present in rheumatic patients. Higher fear levels seem to be associated with comorbidity burden. Unauthorized change of immunosuppressive medication was rare in our study (5%). In our study we provide novel insight into patients’ point of view and behavior of rheumatic patients. Unauthorized change of immunosuppressive medication was rare (5%) as seen in other studies. The low rate of unauthorized change and high rate of compliance is reassuring since good disease control appears to be prognostically important in the progression of COVID-19 disease. Therefore, as the pandemic continues, treatment decisions should be made in close consultation between patient and practitioner to improve adherence and reduce morbidity and mortality.
引用
收藏
页码:1363 / 1367
页数:4
相关论文
共 99 条
  • [1] Schulze-Koops H(2020)Preliminary recommendations of the German Society of Rheumatology (DGRh eV) for the management of patients with inflammatory rheumatic diseases during the SARS-CoV-2/COVID-19 pandemic Ann Rheum Dis 79 840-842
  • [2] Specker C(2021)Treatment adherence of patients with systemic rheumatic diseases in COVID-19 pandemic Ann Rheum Dis 80 e60-384
  • [3] Iking-Konert C(2021)Treatment adherence behaviours in rheumatic diseases during COVID-19 pandemic: a latin American experience Ann Rheum Dis 80 e85-2051
  • [4] Holle J(2020)Adjustment of immunosuppressive therapy in patients with inflammatory-rheumatic diseases in the context of the COVID-19 pandemic - a situation analysis [in German] Z Rheumatol 79 379-791
  • [5] Moosig F(2022)Changes of immunosuppressive medication because of COVID-19 by patients with chronic inflammatory rheumatic diseases: anxiety was not a major driver Clin Exp Rheumatol 40 2044-942
  • [6] Krueger K(2011)High disease activity is associated with an increased risk of infection in patients with rheumatoid arthritis Ann Rheum Dis 70 785-undefined
  • [7] Fragoulis GE(2021)Factors associated with COVID-19-related death in people with rheumatic diseases: results from the COVID-19 global rheumatology alliance physician-reported registry Ann Rheum Dis 80 930-undefined
  • [8] Evangelatos G(undefined)undefined undefined undefined undefined-undefined
  • [9] Arida A(undefined)undefined undefined undefined undefined-undefined
  • [10] Bournia V-K(undefined)undefined undefined undefined undefined-undefined